glp-1 agonist and gastroparesis Gastrointestinal manifestations of diabetes mellitus GI Adverse Effects of Glucagon-Like
Description
Semaglutide was removed in February 2025
Here, we provide a comprehensive review of the therapeutic potential of incretin mimetics and insulin in AD and PD.
Todays DietitianVol
start in minutes.
Evidence-based comparison of retatrutide (GIP/GLP-1/glucagon triple agonist) and survodutide (GLP-1/glucagon dual agonist) for weight loss, MASH, and metabolic disease based on Phase 2 clinical trial data.
however, GLP-1 receptor agonists were associated with a higher risk of discontinuation of endoscopy, possibly owing to a higher risk of retained gastric content
